PAHO Revolving Fund

For more than 40 years, PAHO’s Revolving Fund for Access to Vaccines has provided Member States and Territories throughout the region with access to safe, quality vaccines at affordable prices. It is part of PAHO's larger technical cooperation package that supports countries' efforts to achieve sustainable reductions in the morbidity and mortality of vaccine-preventable diseases through control and elimination strategies.

By consolidating forecasted demand requirements and leveraging economies of scale, promoting transparent negotiations with suppliers, and implementing innovative acquisition strategies, the Revolving Fund greatly improves its purchasing power, lowering vaccine prices and contributing to the sustainability of National Immunization Programs.

What is the PAHO Revolving Fund for Access to Vaccines?

The Revolving Fund for Access to Vaccines, an Engine of Equity

Revolving Fund Brochure

PQS Device Catalogue

Revolving Fund Prices

Technical Cooperation

The Revolving Fund (RFV) provides technical cooperation to national immunization programs to improve their vaccine demand planning and forecasting capacities, strengthen supply chain management, and ensure their financing and sustainability. This cooperation is aligned with the recommendations and guidelines of PAHO’s technical program, the Comprehensive Immunization Special Program (CIM).

Through timely supply, the Revolving Fund has supported participating Member States by:

Elimination of polio, measles, and rubella.
Maintaining vaccination coverage of over 80%.
Cover over 95% of Member States’ vaccination costs with national budgets.

Unique Benefits of the Revolving Fund

Countries would have paid at least 75% more for the Region's 13 most-used routine vaccines
Continuous support from Member States
More than 40 years of experience
WHO-prequalified vaccines and high-quality, efficacious recommended products

Response to the COVID-19 Pandemic

The PAHO Revolving Fund, an implementing partner of the COVAX Facility, supported countries and territories in the Americas in accessing COVID-19 vaccines. As part of the preparations to roll out COVID-19 vaccines, PAHO reviewed countries’ national vaccination and deployment plans, helped with planning, coordination, cold chain, costing and funding, identifying target populations, delivery strategies, and vaccine safety monitoring.

For more information on the COVAX Facility, visit Gavi: COVAX facility and WHO: COVAX facility.

PAHO also advocated for donations to the Americas region. It was involved in planning and operations for bilateral donations and COVAX donated doses from Sweden, Norway, Spain, and Canada, among others, and removed bottlenecks with donors.

In addition, as requested by Member States (MS), the PAHO RF facilitated regional access to additional COVID-19 vaccines during Q4 2021 and 2022.

As of October 2022, 155 million vaccines were allocated through the COVID-19 Vaccine Global Access (COVAX) Facility and delivered by the Revolving Fund for Access to Vaccines.

Yes. You can find more information in the links provided below:

PAHO's response to the COVID-19 pandemic in the Region

Evaluation of the Pan American Health Organization Response to COVID-19 2020–2022. Volume I. Final Report

Pan American Health Organization Response to COVID-19 2022. Summary Report on US Government Funding Allocated under the American Rescue Plan Act

Revolving Fund Product Portfolio

The PAHO Revolving Fund Product Portfolio is the collection of products offered to the Countries and territories in Latin America and the Caribbean to be used in the Immunization Programs. The Portfolio includes product detailed information to support Member States with the procurement planning.

Biological Products

Syringes AD and Disposable

Other Products

BCG
Cholera
DPT (pediatric)
DPT Hib Lyophilized (Pediatric)
DTwP-HepB+Hib (Pentavalent) Liquid (Pediatric)
dT (Adult) - DT (Pediatric)
Tdap Triple Acellular Adolescent/Adult
DTaP Triple Acellular (Pediatric)
DTaP-IPV (Tetravalent
DTaP-IPV-Hib (Pentavalent Acellular) (Pre-filled Syringe) Acellular) (Pre-filled Syringe)
DTaP-IPV-Hep B-Hib (Hexavalent Acellular)
Hepatitis "A" Adult (Vial and Pre-filled Syringe)
Hepatitis "A" Pediatric
Hepatitis B Recombinant Adult
Hepatitis B Recombinant Pediatric
Hib Lyophilized - Meningococcal ACYW135
Inactivated Polio (IPV) - Seasonal Influenza Vaccine
Measles-Rubella - Measles/Mumps (Jeryl-Lynn)/Rubella
Measles/Mumps (Zagreb)/Rubella
Oral Polio Bivalent (bOPV)
Pneumococcal Conjugated Pediatric
10 Valent (PCV-10)
Pneumococcal Conjugated Pediatric
13 Valent (PCV-13)
Pneumococcal Unconjugated Adult
23 valent
Rabies Canine
Rabies Vaccine Human Use / Vero Cells - Rotavirus Liquid (2 dose immunization scheme) - Typhoid Polysaccharide - Varicella - Yellow Fever

Syringe of single use with a re-use prevention feature in a blister packed with fixed needle.

Pre-qualified: Yes E008/
Presentation: Box x 100 pcs
Shelf life: Minimum 24 months at time of shipment (total shelf life 52 months)
Syringe Price: Link prices 2019
Mode of transportation:
- Air: quantities under 200,000 pcs
- Ocean: quantities above 200,000 pcs
Storage Conditions: between 15 and 25 °C
Estimate Delivery time:
- Air - Confirmed in annual demand: 6 - 8 weeks after placing purchase order
- Ocean - Confirmed in annual demand: 12 - 13 weeks after placing purchase order
- Air - Additional demand: 10 – 12 weeks after placing purchase order
- Ocean - Additional demand: 16 – 18 weeks after placing purchase order
Syringe Availability overview in the region: there is enough supply to meet the confirmed requirements of our Members for 2019. Suppliers are reliable and with enough production capacity in case of an increase in the demand.